Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor

Retina

Volumn 30, Issue 7, 2010, Pages 1051-1057

  Mezad Koursh, Daphna ^a,b   Goldstein, Michaella ^a,b   Heilwail, Gad ^a,b   Zayit Soudry, Shiri ^a,b   Loewenstein, Anat ^a,b   Barak, Adiel ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CEFTAZIDIME; FIBRIN; PENICILLIN G; RANIBIZUMAB; SILICONE OIL; TRIAMCINOLONE ACETONIDE; VANCOMYCIN;

ADULT; AGED; ANTERIOR EYE CHAMBER; ANTIBIOTIC THERAPY; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; CORNEA; ENDOPHTHALMITIS; ENTEROCOCCUS FAECALIS; EYE PAIN; EYE SYNECHIA; FEMALE; GLAUCOMA; GRAM POSITIVE BACTERIUM; HUMAN; HYPOPYON; MALE; RETINA DETACHMENT; RETROSPECTIVE STUDY; STREPTOCOCCUS; VISUAL ACUITY; VITRECTOMY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; BACTERIA; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY;

EID: 77954697544     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181cd47ed     Document Type: Article

References (20)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age related macular degeneration. N Engl J Med 2006;355:1419-1431.
2. Heier JS, Boyer DS, Ciulla TA, et al. FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124: 1532-1542.
3. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006;355: 1432-1444.
4. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
5. Rosenfeld PJ, Moshfegi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
6. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
7. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al; Pan- American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114: 743-750.
8. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-1712.
9. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961-969.
10. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518-522.
11. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007;144:864-871. (Pubitemid 350122344)
12. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008; 145:879-882.
13. The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110:979-986.
14. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633.
15. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin [R]): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87.
16. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115:1911-1915.
17. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg 1997;13:388-391.
18. Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities hand motion and counting fingers can be quantified with the Freiburger visual acuity test. Invest Ophthalmol Vis Sci 2006;47:1236-1240.
19. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-1496.
20. Kuhn F, Gini G. Ten years after . . . are findings of the Endophthalmitis Vitrectomy Study still relevant today? Graefes Arch Clin Exp Ophthalmol 2005;243:1197-1199